Fusobacterium Nucleatum Is a Risk Factor for Metastatic Colorectal Cancer

Overview

Journal Curr Med Sci

Specialty General Medicine

Date 2022 Jun 9

PMID 35678912

Authors

Wen-Dan Chen

Xin Zhang

Ya-Ping Zhang

Cong-Bo Yue

Yan-Lei Wang

Hong-Wei Pan

Yan-Li Zhang

Hui Liu

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Increasing evidence has indicated that there is a correlation between Fusobacterium nucleatum (F. nucleatum) abundance and poor prognosis of colorectal cancer (CRC). Furthermore, tumor metastasis plays a decisive role in the prognosis of CRC patients. Therefore, it was hypothesized that the abundance of F. nucleatum in CRC tissues affects the tumor metastasis.

Methods: In the present study, F. nucleatum DNA obtained from 141 resected CRC samples was quantified by qPCR to determine whether there were differences in F. nucleatum abundance between groups with and without CRC metastasis.

Results: The results revealed that F. nucleatum was more abundant in CRC patients with metastasis, and CRC tissues enriched with F. nucleatum had a higher risk of lymph node metastasis and distant metastasis. The receiver operating characteristic curve indicated that F. nucleatum in CRC tissues could be used as an indicator for CRC metastasis, to some extent. Furthermore, the in vitro experiments (electron microscopy, and migration and invasion trials) revealed that F. nucleatum was a highly invasive bacterial strain, and could significantly enhance the invasion and migration capacity of SW480 and SW620 cells. In addition, a meta-analysis comprehensively indicated a slight correlation between F. nucleatum abundance and advanced CRC stage (RR=1.17, 95% CI: 1.00-1.37, P=0.04, random effect).

Conclusion: There is a correlation between F. nucleatum abundance and CRC metastasis, and F. nucleatum may serve as a metastasis biomarker for CRC patients.

Citing Articles

Is the oral pathogen, Porphyromona gingivalis, associated to colorectal cancer?: a systematic review.

Navarro-Sanchez A, Nieto-Vitoria M, Lopez-Lopez J, Martinez-Crespo J, Navarro-Mateu F BMC Cancer. 2025; 25(1):395.

PMID: 40038641 PMC: 11881450. DOI: 10.1186/s12885-025-13770-4.

Gut Microbiome and colorectal cancer: discovery of bacterial changes with metagenomics application in Turkısh population.

Ulger Y, Delik A, Akkiz H Genes Genomics. 2024; 46(9):1059-1070.

PMID: 38990271 DOI: 10.1007/s13258-024-01538-2.

Promising dawn in tumor microenvironment therapy: engineering oral bacteria.

Wang Z, Sun W, Hua R, Wang Y, Li Y, Zhang H Int J Oral Sci. 2024; 16(1):24.

PMID: 38472176 PMC: 10933493. DOI: 10.1038/s41368-024-00282-3.

Transcriptomic analysis of Porphyromonas gingivalis-infected head and neck cancer cells: Identification of PLAU as a candidate prognostic biomarker.

Hamada M, Inaba H, Nishiyama K, Yoshida S, Yura Y, Matsumoto-Nakano M J Cell Mol Med. 2024; 28(4).

PMID: 38363001 PMC: 10870695. DOI: 10.1111/jcmm.18167.

A rapid and sensitive CRISPR-Cas12a for the detection of .

Qu H, Zhang W, Li J, Fu Q, Li X, Wang M Microbiol Spectr. 2024; 12(2):e0362923.

PMID: 38197659 PMC: 10845955. DOI: 10.1128/spectrum.03629-23.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Bruckner H, Motwani B . Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol. 1991; 18(5):443-61. View

Siegel R, Miller K, Sauer A, Fedewa S, Butterly L, Anderson J . Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70(3):145-164. DOI: 10.3322/caac.21601. View

Zhang K, Peng T, Yan Q, Sun L, Miao H, Yuan L . Jiedu Sangen Decoction Inhibits Migration and Invasion of Colon Cancer SW480 Cells via Suppressing Epithelial Mesenchymal Transition. Evid Based Complement Alternat Med. 2018; 2018:1495768. PMC: 6176311. DOI: 10.1155/2018/1495768. View

Tuomisto A, Norskov N, Sirnio P, Vayrynen J, Mutt S, Klintrup K . Serum enterolactone concentrations are low in colon but not in rectal cancer patients. Sci Rep. 2019; 9(1):11209. PMC: 6671944. DOI: 10.1038/s41598-019-47622-6. View

Grech G, Zhan X, Yoo B, Bubnov R, Hagan S, Danesi R . EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015; 6(1):9. PMC: 4407842. DOI: 10.1186/s13167-015-0030-6. View

Janney A, Powrie F, Mann E . Host-microbiota maladaptation in colorectal cancer. Nature. 2020; 585(7826):509-517. DOI: 10.1038/s41586-020-2729-3. View

Zhou Z, Chen J, Yao H, Hu H . and Colorectal Cancer. Front Oncol. 2018; 8:371. PMC: 6196248. DOI: 10.3389/fonc.2018.00371. View

Hong B, Ideta T, Lemos B, Igarashi Y, Tan Y, DiSiena M . Characterization of Mucosal Dysbiosis of Early Colonic Neoplasia. NPJ Precis Oncol. 2019; 3:29. PMC: 6856115. DOI: 10.1038/s41698-019-0101-6. View

10.

Han Y . Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol. 2015; 23:141-7. PMC: 4323942. DOI: 10.1016/j.mib.2014.11.013. View

11.

Shet U, Oh H, Kim H, Chung H, Kim Y, Kim O . Quantitative analysis of periodontal pathogens present in the saliva of geriatric subjects. J Periodontal Implant Sci. 2013; 43(4):183-90. PMC: 3769597. DOI: 10.5051/jpis.2013.43.4.183. View

12.

Allen-Vercoe E, Jobin C . Fusobacterium and Enterobacteriaceae: important players for CRC?. Immunol Lett. 2014; 162(2 Pt A):54-61. PMC: 4259803. DOI: 10.1016/j.imlet.2014.05.014. View

13.

Goradel N, Heidarzadeh S, Jahangiri S, Farhood B, Mortezaee K, Khanlarkhani N . Fusobacterium nucleatum and colorectal cancer: A mechanistic overview. J Cell Physiol. 2018; 234(3):2337-2344. DOI: 10.1002/jcp.27250. View

14.

Wang S, Liu Y, Li J, Zhao L, Yan W, Lin B . Acts as a Pro-carcinogenic Bacterium in Colorectal Cancer: From Association to Causality. Front Cell Dev Biol. 2021; 9:710165. PMC: 8417943. DOI: 10.3389/fcell.2021.710165. View

15.

Slade D . New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?. Trends Cancer. 2020; 7(3):185-187. DOI: 10.1016/j.trecan.2020.11.006. View

16.

Kostic A, Gevers D, Pedamallu C, Michaud M, Duke F, Earl A . Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2011; 22(2):292-8. PMC: 3266036. DOI: 10.1101/gr.126573.111. View

17.

Li Y, Ge Q, Cao J, Zhou Y, Du Y, Shen B . Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol. 2016; 22(11):3227-33. PMC: 4789998. DOI: 10.3748/wjg.v22.i11.3227. View

18.

Castellarin M, Warren R, Freeman J, Dreolini L, Krzywinski M, Strauss J . Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2011; 22(2):299-306. PMC: 3266037. DOI: 10.1101/gr.126516.111. View

19.

Rubinstein M, Wang X, Liu W, Hao Y, Cai G, Han Y . Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013; 14(2):195-206. PMC: 3770529. DOI: 10.1016/j.chom.2013.07.012. View

20.

Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z . Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015; 6:6528. DOI: 10.1038/ncomms7528. View